Operations

Survey shows sites use EMR systems for recruiting but not for source data collection

April 20, 2018

In a survey commissioned by Clinical Research IO (CRIO), 62% of sites, who mainly conduct non-oncology trials, reported that they use their Electronic Medical Record (EMR) system as their primary system for recruiting patients, but only 13% reported that they use their EMR as their primary system for source data collection. For source data collection, […]

Allergan Does Not Intend to Make an Offer for Shire plc; Strategic Review Continues

April 20, 2018

DUBLIN, April 19, 2018 /PRNewswire/ — In order to comply with the requirements of the UK Takeover Code, Allergan announced that it does not intend to make an offer for Shire.   Allergan continues its ongoing process of evaluating a full range of potential strategic actions that will create value for shareholders, such as divestitures, […]

Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease

April 20, 2018

SAN FRANCISCO & TEL AVIV, Israel–(BUSINESS WIRE)–Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) today announced that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,889,100 B2 with claims covering the use of cannabidiol (“CBD”) for the treatment of severe and refractory graft versus host disease (“GVHD”). […]

Atreca Announces John A. Orwin Appointed President and CEO

April 20, 2018

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that John A. Orwin, formerly CEO of Relypsa, has been appointed President and Chief Executive Officer of Atreca. He will also serve on the Company’s Board of Directors. Mr. Orwin […]

Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations

April 20, 2018

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President, Commercial Operations. Mr. Biehn brings over 27 years of commercial planning, market development and sales experience in the pharmaceutical industry. […]

Neurotechnology Innovations Translator (NIT) Announces Funding of up to $50 Million in Portfolio Company, Sollis Therapeutics

April 20, 2018

COLUMBUS, Ohio–(BUSINESS WIRE)–NeuroTechnology Innovations Translator (NIT), an Ohio-based translator focused on advancing development and commercialization of innovative neurotechnology solutions, announced the closing of funding of up to $50 million in its second portfolio company, Sollis Therapeutics (Sollis). Sollis’ much anticipated new therapy is designed to locally deliver a non-opioid analgesic and anti-inflammatory medication for rapid […]

Cynata Therapeutics Completes Patent Application to Cover Cymerus™ Stem Cell Technology in the Treatment of Side Effects Related to CAR-T Therapy

April 20, 2018

MELBOURNE, Australia, April 20, 2018 (GLOBE NEWSWIRE) — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), today announced that it has completed the filing of a patent application with IP Australia that would cover the therapeutic use of its Cymerus™ stem cell technology in the treatment of adverse reactions associated with chimeric […]

UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

April 20, 2018

BRUSSELS, April 20, 2018 /PRNewswire/ —   Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of […]

Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities Laws

April 20, 2018

SAN DIEGO, April 20, 2018 (GLOBE NEWSWIRE) — Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, initiated a lawsuit in the United States District Court for the Southern District of California on April 19, 2018 against former President and Chief Executive Officer (CEO), Joseph E. Payne, and his associates, including Bradley Sorenson, Peter Farrell […]

SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer

April 20, 2018

NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the appointment of Gene Mack as Chief Financial Officer and Treasurer. “We are delighted to welcome Gene to our executive team. He […]

Atossa Genetics Announces 1 for 12 Reverse Stock Split

April 20, 2018

SEATTLE, April 20, 2018 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced a reverse split of its common stock at a ratio of 1-for-12, effective April 20, 2018. The reverse split was approved by the Company’s stockholders […]

Sterling invests £6m in pilot plant facility

April 20, 2018

Contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions is investing £6m into its pilot plant facility at its UK site to enhance its scale-up and small to midscale commercial API manufacturing capabilities. The expansion will increase the pilot plant’s capacity by 33% and enhance the site’s production capabilities and flexibility for small to mid-scale […]

Cathy Collins leads new corporate team at Meridien Research after acquisition

April 19, 2018

Tampa, FL – Cathy Collins, backed by Avego Healthcare Capital, has completed the acquisition of Meridien Research, returning to her former role as Chief Executive Officer (CEO). Along with Meridien’s new Chief Operating Officer (COO), Stacey Colado, she joins current Chief Medical Officer (CMO), Andrew Cutler, MD to form the new leadership team. Meridien Research […]

ViaCyte Substantially Expands Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

April 18, 2018

SAN DIEGO, April 17, 2018 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company, today announced the recent issuance of more than 200 patents, which provide protection to the company’s core technologies around the world. The newly issued patents further strengthen ViaCyte’s already strong position in pluripotent cell-derived and implantable cell replacement therapies for insulin-requiring […]

Stoke Therapeutics Expands Leadership Team, Building on Deep Expertise in Oligonucleotide Chemistry and Rare Disease Research and Development

April 18, 2018

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc., a biotechnology company developing therapeutics that increase gene expression to treat a wide array of diseases caused by genetic insufficiency, today announced the expansion of its leadership team to enhance its deep expertise in oligonucleotide chemistry and rare disease research and development.   Gene Liau, Ph.D., a veteran biopharma executive […]

Altan Pharma Announces the Grant of Two Patents by the USPTO Covering its Unique, Intravenous Formulation of Acetaminophen

April 18, 2018

DUBLIN–(BUSINESS WIRE)–Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted two patents to Altan covering its intravenous formulation of acetaminophen (paracetamol).   U.S. Patent No. 9,943,479 covers Altan’s unique formulation, which allows the product to be packaged in a flexible plastic container […]

Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

April 18, 2018

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $7.50 per […]

VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer

April 18, 2018

SEATTLE, WA, April 17, 2018 (GLOBE NEWSWIRE) — VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of Randal Buness, CPA, MBA as Chief Financial Officer.   Mr. Buness is a senior financial executive with over 25 years of results-oriented leadership. Prior to joining VisionGate, he served as Chief […]

Oncolytics Biotech® Announces Management Change

April 18, 2018

CALGARY, AB and SAN DIEGO, CA — (Marketwired) — 04/17/18 — Oncolytics Biotech® Inc. (TSX: ONC)(OTCQX: ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus creating an inflamed phenotype, today announced that Andres Gutierrez, Chief Medical Officer at Oncolytics, will be leaving to pursue other opportunities, effective April 23, 2018. “Doctor Gutierrez joined Oncolytics […]

Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy

April 18, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). Catabasis is prioritizing this program to deliver against its goal of bringing a life changing therapy to those affected by […]

Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer

April 18, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced the appointment of John C. King as Chief Commercial Officer, effective April 16, 2018. Mr. King brings to Ra Pharma more than 20 years of senior, global, commercial leadership […]

Grid Therapeutics Closes Series B Financing

April 18, 2018

DURHAM, N.C.–(BUSINESS WIRE)–Grid Therapeutics, LLC, a biotechnology company developing a first-in-class, novel human-derived targeted immunotherapy for cancer, today announced the closing of its Series B financing. Grid will use the proceeds from the financing to accelerate and expand the development of Grid’s lead therapeutic candidate, GT103, for the treatment of solid tumors, and to prepare […]

Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

April 18, 2018

SANTA MONICA, Calif., April 18, 2018 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), […]

GSK appoints Kevin Sin as new SVP and Head of Worldwide Business Development for R&D

April 18, 2018

GlaxoSmithKline plc (GSK) today announced the appointment of Kevin Sin as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development. In this position, Kevin will play a critical role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of innovative new medicines for patients. Kevin will join […]

FEEDBACK